QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
NASDAQ:RLYB

Rallybio (RLYB) Stock Price, News & Analysis

$2.22
+0.10 (+4.72%)
(As of 02/28/2024 ET)
Today's Range
$2.12
$2.38
50-Day Range
$1.25
$2.64
52-Week Range
$1.23
$9.88
Volume
431,965 shs
Average Volume
277,269 shs
Market Capitalization
$83.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.20

Rallybio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
494.6% Upside
$13.20 Price Target
Short Interest
Bearish
6.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Rallybio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.80) to ($1.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.46 out of 5 stars

Medical Sector

313th out of 959 stocks

Pharmaceutical Preparations Industry

137th out of 435 stocks


RLYB stock logo

About Rallybio Stock (NASDAQ:RLYB)

Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

RLYB Stock Price History

RLYB Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Rallybio Corp RLYB
Expert Ratings for Rallybio
Rallybio GAAP EPS of -$0.45
Rallybio: Q3 Earnings Insights
See More Headlines
Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
2/28/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RLYB
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.20
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+480.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-66,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.29 per share

Miscellaneous

Free Float
35,602,000
Market Cap
$85.97 million
Optionable
Not Optionable
Beta
-2.05
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Martin W. MacKay Ph.D. (Age 68)
    Co-Founder & Executive Chairman
    Comp: $707.07k
  • Dr. Stephen Uden M.B (Age 66)
    M.D., Co-Founder, President, CEO & Director
    Comp: $707.07k
  • Mr. Jonathan I. Lieber M.B.A. (Age 54)
    CFO & Treasurer
  • Ms. Ami Bavishi
    Head of Investor Relations & Corporate Communications
  • Dr. Steven W. Ryder F.A.C.P (Age 72)
    M.D., Chief Medical Officer














RLYB Stock Analysis - Frequently Asked Questions

Should I buy or sell Rallybio stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RLYB shares.
View RLYB analyst ratings
or view top-rated stocks.

What is Rallybio's stock price target for 2024?

6 Wall Street analysts have issued twelve-month price objectives for Rallybio's shares. Their RLYB share price targets range from $8.00 to $18.00. On average, they expect the company's stock price to reach $13.20 in the next year. This suggests a possible upside of 494.6% from the stock's current price.
View analysts price targets for RLYB
or view top-rated stocks among Wall Street analysts.

How have RLYB shares performed in 2024?

Rallybio's stock was trading at $2.39 at the beginning of 2024. Since then, RLYB stock has decreased by 7.1% and is now trading at $2.22.
View the best growth stocks for 2024 here
.

Are investors shorting Rallybio?

Rallybio saw a increase in short interest in February. As of February 15th, there was short interest totaling 1,080,000 shares, an increase of 43.4% from the January 31st total of 753,400 shares. Based on an average trading volume of 222,900 shares, the days-to-cover ratio is presently 4.8 days. Approximately 6.3% of the company's stock are short sold.
View Rallybio's Short Interest
.

When is Rallybio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our RLYB earnings forecast
.

How were Rallybio's earnings last quarter?

Rallybio Co. (NASDAQ:RLYB) issued its quarterly earnings results on Monday, March, 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.14.

When did Rallybio IPO?

(RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share.

Who are Rallybio's major shareholders?

Rallybio's stock is owned by many different institutional and retail investors. Top institutional investors include Novo Holdings A S (4.68%), abrdn plc (4.57%), Vanguard Group Inc. (2.82%), Blue Owl Capital Holdings LP (0.93%), Citadel Advisors LLC (0.84%) and Northern Trust Corp (0.66%). Insiders that own company stock include Jeffrey M Fryer, Jonathan I Lieber, Kush Parmar, Martin Mackay, Opportunities I LP 5Am and Stephen Uden.
View institutional ownership trends
.

How do I buy shares of Rallybio?

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLYB) was last updated on 2/28/2024 by MarketBeat.com Staff